Full Press Release Details
QED Therapeutics Presents Data For Infigratinib In Cholangiocarcinoma In Late Breaking Abstract At The European Society Of Medical Oncology 2018 Congress.
BBIO
QED Therapeutics Presents Data For Infigratinib In Cholangiocarcinoma In Late Breaking Abstract At The European Society Of Medical Oncology 2018 Congress
Key Takeaway: QED Therapeutics Presents Data For Infigratinib In Cholangiocarcinoma In Late Breaking Abstract At The European Society Of Medical Oncology 2018 Congress